Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis

Launched by POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH · Dec 1, 2021

Keywords

ClinConnect Summary

This clinical trial is comparing two different types of radiation treatments for patients with breast cancer that has spread to the brain. One treatment is called Stereotactic Radiosurgery (SRS), which targets the tumors very precisely, while the other is Whole Brain Radiotherapy (WBRT), which treats the entire brain. The main goals of the study are to see which treatment helps patients live longer, how well it controls the cancer, the side effects of each option, and how each treatment affects the patients’ quality of life.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed diagnosis of breast cancer with 1 to 3 brain tumors that are no larger than 3 cm. They should be in fairly good health and able to perform daily activities without much difficulty. The trial is currently recruiting participants, and those who join will receive either SRS or WBRT based on the size of their tumors. It's important for potential participants to know that they cannot have had previous radiation treatment for brain cancer or have serious other health problems. Overall, this study aims to find out which treatment option is better for patients dealing with this challenging situation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \>=18 years
• • Willing to provide informed consent
• • Histologically confirmed malignancy with metastatic disease detected on imaging.
• • ECOG performance status 0-1
• • 1 to 3 brain metastases, each with a maximum diameter of no more than 3 cm on contrast enhanced magnetic resonance imaging(MRI) scans
• Exclusion Criteria:
• • Serious medical comorbidities
• • ECOG \>= 2
• • Prior Brain Radiotherapy
• • \>3 brain metastasis
• • Maximum diameter \>4cm on MRI